Close Menu

A University of Pennsylvania-led team introduces software for teasing out the effects of non-coding variants found in genome-wide association studies. The approach — called "Inferring the molecular mechanisms of noncoding genetic variants," or INFERNO — quantifies tissue-specific enhancers and other regulatory features using statistical methods informed by transcription factor, expression quantitative trait locus, and other functional genomic datasets, the researchers explain.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.